Author Archives: 瑶 翟

Henlius Biotech’s innovative anti-PD-L1/VEGF bispecific antibody HLX37 has received approval for clinical trials by the China NMPA, marking a significant development in immuno-oncology. This dual-target antibody combines immune checkpoint inhibition and anti-angiogenesis, enhancing the synergy between immunotherapy and tumor microenvironment modulation. It underscores the growing influence of domestic biologics in the global immuno-oncology landscape and highlights the need for a deeper understanding of the PD-1/PD-L1 pathway’s structure, regulation, and signaling mechanisms for overcoming resistance and improving precision treatment strategies.

In recent years, immunotherapy targeting the PD-1/PD-L1 axis has rapidly evolved, moving beyond first-generation monoclonal antibodies to include PD-1/VEGF bispecific antibodies, PD-L1 ADCs, and various combination strategies. Clinical development and capital markets are shifting upstream, with landmark transactions like SSGJ-707 highlighting the commercial value of immune checkpoint inhibitors. Key industry insight: differentiation and long-term success depend not on pursuing immuno-oncology, but on choosing the right target and approach. Understanding the biological rationale and clinical implications of PD-1 versus PD-L1 targeting requires a deep dive into the signaling pathway itself.